<--GAT-->

Paliperidone Palmitate Helps Some Schizophrenia Patients

by U.S. Medicine

October 16, 2017

WHITE RIVER JUNCTION, VT — Even though nearly half of all patients diagnosed with schizophrenia have a history of substance abuse (SA), data on treatment of schizophrenia with paliperidone palmitate (PP) among patients with comorbid SA have been limited.

A study published in the journal Clinical Therapeutics compared all-cause and SA-related healthcare resource utilization and costs in veterans with schizophrenia and co-occurring SA who were treated with PP vs.oral atypical antipsychotics (OAAs).1

A team including researchers from the White River Junction, VT, VAMC employed VHA electronic health record data to conduct a retrospective longitudinal study in veterans with schizophrenia who initiated PP or OAA between Jan. 1, 2010, and June 30, 2016. Participants had more than 12 months of enrollment before treatment initiation (baseline), were diagnosed with SA, and had one or fewer Global Assessment of Functioning score during baseline.

Researchers estimated adjusted cost differences and incidence rate ratios (IRR) for the association between PP vs. OAA and all-cause and SA-related healthcare costs and healthcare resource utilization in the 12 months after treatment initiation.

Results indicated that, of 6,872 veterans in the study, 1,684 (25%) and 5,188 (75%) were treated with PP and OAA, respectively.

After adjustment, PP was associated with fewer all-cause inpatient (IRR = 0.88), mental health-related inpatient (IRR = 0.88) and long-term care stays (IRR = 0.53) compared with OAA. It was associated with more frequent mental health intensive case management visits (IRR = 1.51), however.

At the same time, PP was associated with significantly lower rates of SA-related inpatient stays (IRR = 0.80), mental health stays (IRR = 0.85) long-term care stays (IRR = 0.22) and outpatient visits (IRR = 0.78) than OAA, study authors reported.

Treatment with PP also saved money compared to OAA, the report noted. Patients treated with PP also had lower mean annual all-cause $10,473 lower cost, and SA-related, $8,457 lower cost.

 “PP was associated with significant total medical cost savings resulting from fewer hospitalizations and lower rates of SA-related health care resource utilization compared with OAA in patients with schizophrenia and comorbid SA,” study authors concluded. “Thus, PP appears to be a valuable treatment option for patients in this subpopulation.”

1. Lefebvre P, Muser E, Joshi K, DerSarkissian M, Bhak RH, Duh MS, Shiner B,Young-Xu Y. Impact of Paliperidone Palmitate Versus Oral Atypical Antipsychotics on Health Care Resource Use and Costs in Veterans With Schizophrenia and ComorbidSubstance Abuse. Clin Ther. 2017 Jul;39(7):1380-1395.e4. doi:10.1016/j.clinthera.2017.05.356. Epub 2017 Jun 20. PubMed PMID: 28641996.


Comments are closed here.


Related Articles

Senate VA Committee Chair Vows to Pass ‘Blue Water’ Navy Benefits

Senate Committee on Veterans' Affairs Chairman Sen. Johnny Isakson (R-GA) vowed that addressing benefits for Blue Water Navy Veterans “is no longer going to be a question,” but that “how we do it is the only question.”

Suicide Rates Jump Up for Younger Veterans in Recent Years

Rates of suicide among younger veterans (ages 18-34) “increased substantially in recent years,” climbing from 40.4 suicide deaths per 100,000 population in 2015 to 45 suicide deaths per 100,000 population in 2016, according to a new report.


U.S. Medicine Recommends


More From department of veterans affairs

Department of Veterans Affairs (VA)

Senate VA Committee Chair Vows to Pass 'Blue Water' Navy Benefits

Senate Committee on Veterans' Affairs Chairman Sen. Johnny Isakson (R-GA) vowed that addressing benefits for Blue Water Navy Veterans “is no longer going to be a question,” but that “how we do it is the only question.”

Department of Veterans Affairs (VA)

VHA Makes Progress in Improving Safety of Opioid Prescribing

VHA medical facilities should ensure that its providers are following three key opioid risk mitigation strategies, including conducting urine drug screening, a recent report recommended.

Department of Veterans Affairs (VA)

VA faces healthcare staffing shortages, barriers to hiring facility leaders

A facility-specific survey found that 138 of 140 VA facilities reported shortages of medical officers, with psychiatry and primary care positions being the most frequently listed.

Department of Veterans Affairs (VA)

Veteran nephrologist labors to improve ESRD treatment at VA

When Terrence O’Neil, MD, retired as chief of nephrology at the James H. Quillen VAMC in Johnson City in December 2016, he left in his wake decades of work treating kidney disease—nearly 35 years in the Air Force and DoD, plus 11 more at VA.

Department of Veterans Affairs (VA)

Committee approves bill to provide agent orange benefits to ‘blue water’ vets

A long sought-after bill that would make it easier for Blue Water Navy veterans to receive Agent Orange benefits has been passed by a key House of Representatives committee.

Subscribe to U.S. Medicine Print Magazine

U.S. Medicine is mailed free each month to physicians, pharmacists, nurse practitioners, physician assistants and administrators working for Veterans Affairs, Department of Defense and U.S. Public Health Service.

Subscribe Now

Receive Our Email Newsletter

Stay informed about federal medical news, clinical updates and reports on government topics for the federal healthcare professional.

Sign Up